Physiomics (GB:PYC) has released an update.
Physiomics PLC, a specialist in mathematical modelling for new therapeutics, has secured a £65k contract to update two of its proprietary Virtual Tumour models for an existing large pharma client, using new clinical data to aid in oncology therapy decisions. The project is expected to be completed within the current year, marking continued success in the Company’s client partnerships and service impact. CEO Dr. Peter Sargent expresses delight in this contract win, underscoring the company’s commitment to long-term client relationships.
For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.
